Compare Abeona Therapeutics Inc (ABEO) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $421.19M), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.63. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | HYG | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Fixed Income |
52-Week High | $7.45 | $81.32 |
52-Week Low | $4.17 | $78.72 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.615, up 0.17% on the day. Technical indicators show a bearish trend with key support at $79 and resistance at $80. Recent news highlights bond market volatility amid inflation concerns and rising oil prices, while the ETF faces criticism for underperformance versus peers.
The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include high-yield credit exposure and inflation sensitivity, but the ETF's 6.5% dividend yield may attract income-focused investors amid broader bond market inflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
